生化防禦的全球市場 - 全球產業分析(2019年～2022年)- 成長趨勢與市場預測(2023年～2030年)

Biodefense Market - Global Industry Analysis (2019 - 2022), Growth Trends, and Market Forecast (2023 - 2030)

出版日期: 2023年04月12日 | 出版商:

Fairfield Market Research | 英文 175 Pages | 商品交期: 2-5個工作天內

價格

簡介目錄

全球生化防禦的市場規模在2022年估算為148億美金。該市場在預測期間內預計將以6.3％的年複合成長率擴大，2030年達到245億美元。

本報告提供全球生化防禦市場相關調查，提供市場概要，以及各產品類型，各最終用途類型，各地區趨勢，及市場參與市場企業的競爭趨勢等資訊。

The confluence of rising concerns about biothreats and the emergence of infectious diseases has created a demand for biodefense products and services. Recognising this need, government authorities worldwide are making significant investments in biodefense research, development, and procurement programs to ensure public health preparedness and enhance national security. Such a scenario is also influencing strategic partnerships among key players in the biodefense market. These collaborations aim to enhance their capabilities, expand their product portfolios, and strengthen their market presence. Furthermore, the advances in biotechnology, genomics, and proteomics are facilitating the development of innovative biodefense products, and services with enhanced efficacy, specificity, and rapidity.

Additionally, the increasing public awareness of the potential impact of biothreats on health and national security is accelerating efforts to develop biodefense measures. In its latest report, Fairfield Market Research foresees the growth trajectory for the global biodefense market. Registering a revenue worth US$14.8 Bn in 2022, the market is slated for a substantial CAGR of 6.3% over the forecast period and is expected to reach a whopping US$24.5 Bn by 2030.

Key Insights and Trends Across Biodefense Market:

Anthrax category to emerge as a leading product type, accounting for a lion share (30%) of the market

Military segment to establish itself as a frontrunner in the global biodefense market, exhibiting a robust CAGR of 6.2%

North America to sustain market dominance owing to favourable federal funding, reaching a staggering US$20.8 billion by the end of 2030

Infectious Diseases Pose Mounting Threat to Global Health, Spurring Explosive Growth Across Biodefense Market:

Over recent years, the risk of infectious diseases, due to the accidental or deliberate release of chemical, biological, radiological, or nuclear (CBRN) agents, has increased. This in turn has prompted biodefense firms to develop sophisticated diagnostic tools that can detect a wide array of infectious agents, including viruses, bacteria, and fungi. Companies are also investing in research and development to create innovative therapeutics and vaccines. Currently, there is a range of prophylactic, therapeutic, and diagnostic products available for significant biological, chemical and radiation threats. In light of these circumstances, the global biodefense market is projected to gain substantial momentum in the upcoming years.

Advanced Healthcare Infrastructure Puts North America at the Forefront of Global Biodefense Market:

North America is well-positioned to attain a distinct advantage in the global biodefense market. This is primarily attributable to the strong and effective strategies of the United States government. Besides, North America has made significant investments in research and development activities and procurement programs. Apart from this, the region also boasts a well-developed healthcare infrastructure with modern diagnostic and treatment facilities that enable rapid detection and response to biodefense. Such trends are sowing the seed of sustainable growth across North America's biodefense market.

Prominent Market Players:

Some of the key players in the global biodefense market include: Nanotherapeutics, Inc., SIGA Technologies, Inc., Emergent BioSolutions, Inc., Altimmune, Inc., Bavarian Nordic A/S, Statera Biopharma, Inc., GSK plc. Sanofi Pasteur, Dynavax Technologies Corporation, Xoma Corporation, Meridian Medical Technologies, NightHawk Biosciences, Inc., Dynport Vaccine Company LLC, LLC, and Soligenix.

1. Executive Summary

1.1. Global Biodefense Market Outlook, 2019 - 2030 (US$ Million)
1.2. Global Biodefense Market Incremental Opportunity, 2023 - 2030 (US$ Million)
1.3. Key Industry Trends

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Market Drivers
- 2.2.2. Market Threats
- 2.2.3. Market Opportunities
2.3. Regulatory Framework
2.4. COVID 19 Impact Analysis

3. Global Biodefense Market Outlook, 2019 - 2030

3.1. Global Biodefense Market Outlook, By Product Type, 2019 - 2030
- 3.1.1. Key Highlights
- 3.1.2. Global Biodefense Market Outlook, by Product Type, Value (US$ Million), 2019 - 2030
  - 3.1.2.1. Anthrax
  - 3.1.2.2. Smallpox
  - 3.1.2.3. Botulism
  - 3.1.2.4. Chemical
  - 3.1.2.5. Radiation/Nuclear
  - 3.1.2.6. Others
- 3.1.3. Global Biodefense Market Share and BPS Analysis, by Product Type, Value, 2023 and 2030
- 3.1.4. Global Biodefense Market Attractiveness Analysis, by Product Type, Value, 2023 - 2030
3.2. Global Biodefense Market Outlook, By End Use Type, 2019 - 2030
- 3.2.1. Key Highlights
- 3.2.2. Global Biodefense Market Outlook, by End Use Type, Value (US$ Million), 2019 - 2030
  - 3.2.2.1. Military
  - 3.2.2.2. Civil
  - 3.2.2.3. Research Institutes
- 3.2.3. Global Biodefense Market Share and BPS Analysis, by End Use Type, Value, 2023 and 2030
- 3.2.4. Global Biodefense Market Attractiveness Analysis, by End Use Type, Value, 2023 - 2030
3.3. Global Biodefense Market Outlook, By Region, 2019 - 2030
- 3.3.1. Key Highlights
- 3.3.2. Global Biodefense Market Outlook, by Region, Value (US$ Million), 2019 - 2030
  - 3.3.2.1. North America
  - 3.3.2.2. Europe
  - 3.3.2.3. Asia Pacific
  - 3.3.2.4. Rest of the World
- 3.3.3. Global Biodefense Market Share and BPS Analysis, by Region, Value, 2023 and 2030
- 3.3.4. Global Biodefense Market Attractiveness Analysis, by Region, Value, 2023 - 2030

4. North America Biodefense Market Outlook, 2019 - 2030

4.1. North America Biodefense Market Outlook, By Country, 2019 - 2030
- 4.1.1. Key Highlights
- 4.1.2. North America Biodefense Market Outlook, by Country, Value (US$ Million), 2019 - 2030
  - 4.1.2.1. U.S.
  - 4.1.2.2. Canada
- 4.1.3. North America Biodefense Market Share and BPS Analysis, by Country, Value, 2023 and 2030
- 4.1.4. North America Biodefense Market Attractiveness Analysis, by Country, Value, 2023 - 2030
4.2. North America Biodefense Market Outlook, by Product Type, 2019 - 2030
- 4.2.1. Key Highlights
- 4.2.2. North America Biodefense Market Outlook, by Product Type, Value (US$ Million), 2019 - 2030
  - 4.2.2.1. Anthrax
  - 4.2.2.2. Smallpox
  - 4.2.2.3. Botulism
  - 4.2.2.4. Chemical
  - 4.2.2.5. Radiation/Nuclear
  - 4.2.2.6. Others
- 4.2.3. North America Biodefense Market Share and BPS Analysis, by Product Type, Value, 2023 and 2030
- 4.2.4. North America Biodefense Market Attractiveness Analysis, by Product Type, Value, 2023 - 2030
4.3. North America Biodefense Market Outlook, by End Use, 2019 - 2030
- 4.3.1. Key Highlights
- 4.3.2. North America Biodefense Market Outlook, by End Use, Value (US$ Million), 2019 - 2030
  - 4.3.2.1. Military
  - 4.3.2.2. Civil
  - 4.3.2.3. Research Institutes
- 4.3.3. North America Biodefense Market Share and BPS Analysis, by End Use, Value, 2023 and 2030
- 4.3.4. North America Biodefense Market Attractiveness Analysis, by End Use, Value, 2023 - 2030

5. Europe Biodefense Market Outlook, 2019 - 2030

5.1. Europe Biodefense Market Outlook, By Country, 2019 - 2030
- 5.1.1. Key Highlights
- 5.1.2. Europe Biodefense Market Outlook, by Country, Value (US$ Million), 2019 - 2030
  - 5.1.2.1. U.K.
  - 5.1.2.2. France
  - 5.1.2.3. Germany
  - 5.1.2.4. Italy
  - 5.1.2.5. Spain
  - 5.1.2.6. Rest of Europe
- 5.1.3. Europe Biodefense Market Share and BPS Analysis, by Country, Value, 2023 and 2030
- 5.1.4. Europe Biodefense Market Attractiveness Analysis, by Country, Value, 2023 - 2030
5.2. Europe Biodefense Market Outlook, by Product Type, Value (US$ Million), 2019 - 2030
- 5.2.1. Key Highlights
- 5.2.2. Europe Biodefense Market Outlook, by Product Type, Value (US$ Million), 2019 - 2030
  - 5.2.2.1. Anthrax
  - 5.2.2.2. Smallpox
  - 5.2.2.3. Botulism
  - 5.2.2.4. Chemical
  - 5.2.2.5. Radiation/Nuclear
  - 5.2.2.6. Others
- 5.2.3. Europe Biodefense Market Share and BPS Analysis, by Product Type, Value, 2023 and 2030
- 5.2.4. Europe Biodefense Market Attractiveness Analysis, by Product Type, Value, 2023 - 2030
5.3. Europe Biodefense Market Outlook, By End Use Type, 2019 - 2030
- 5.3.1. Key Highlights
- 5.3.2. Europe Biodefense Market Outlook, by End Use Type, Value (US$ Million), 2019 - 2030
  - 5.3.2.1. Military
  - 5.3.2.2. Civil
  - 5.3.2.3. Research Institutes
- 5.3.3. Europe Biodefense Market Share and BPS Analysis, by End Use, Value, 2023 and 2030
- 5.3.4. Europe Biodefense Market Attractiveness Analysis, by End Use, Value, 2023 - 2030

6. Asia Pacific Biodefense Market Outlook, 2019 - 2030

6.1. Asia Pacific Biodefense Market Outlook, By Country, 2019 - 2030
- 6.1.1. Key Highlights
- 6.1.2. Asia Pacific Biodefense Market Outlook, by Country, Value (US$ Million), 2019 - 2030
  - 6.1.2.1. India
  - 6.1.2.2. Japan
  - 6.1.2.3. China
  - 6.1.2.4. Australia
  - 6.1.2.5. Rest of Asia Pacific
- 6.1.3. Asia Pacific Biodefense Market Share and BPS Analysis, by Country, Value, 2023 and 2030
- 6.1.4. Asia Pacific Biodefense Market Attractiveness Analysis, by Country, Value, 2023 - 2030
6.2. Asia Pacific Biodefense Market Outlook, by Product Type, Value (US$ Million), 2019 - 2030
- 6.2.1. Key Highlights
- 6.2.2. Asia Pacific Biodefense Market Outlook, by Product Type, Value (US$ Million), 2019 - 2030
  - 6.2.2.1. Anthrax
  - 6.2.2.2. Smallpox
  - 6.2.2.3. Botulism
  - 6.2.2.4. Chemical
  - 6.2.2.5. Radiation/Nuclear
  - 6.2.2.6. Others
- 6.2.3. Asia Pacific Biodefense Market Share and BPS Analysis, by Product Type, Value, 2023 and 2030
- 6.2.4. Asia Pacific Biodefense Market Attractiveness Analysis, by Product Type, Value, 2023 - 2030
6.3. Asia Pacific Biodefense Market Outlook, By End Use, 2019 - 2030
- 6.3.1. Key Highlights
- 6.3.2. Asia Pacific Biodefense Market Outlook, by End Use, Value (US$ Million), 2019 - 2030
  - 6.3.2.1. Military
  - 6.3.2.2. Civil
  - 6.3.2.3. Research Institutes
- 6.3.3. Asia Pacific Biodefense Market Share and BPS Analysis, by End Use, Value, 2023 and 2030
- 6.3.4. Asia Pacific Biodefense Market Attractiveness Analysis, by End Use, Value, 2023 - 2030

7. Rest of the World Biodefense Market Outlook, 2019 - 2030

7.1. Rest of the World Biodefense Market Outlook, By Country, 2019 - 2030
- 7.1.1. Key Highlights
- 7.1.2. Rest of the World Biodefense Market Outlook, by Country, Value (US$ Million), 2019 - 2030
  - 7.1.2.1. Latin America
  - 7.1.2.2. Middle East & Africa
- 7.1.3. Rest of the World Biodefense Market Share and BPS Analysis, by Country, Value, 2023 and 2030
- 7.1.4. Rest of the World Biodefense Market Attractiveness Analysis, by Country, Value, 2023 - 2030
7.2. Rest of the World Biodefense Market Outlook, by Product Type, 2019 - 2030
- 7.2.1. Key Highlights
- 7.2.2. Rest of the World Biodefense Market Outlook, by Product Type, Value (US$ Million), 2019 - 2030
  - 7.2.2.1. Anthrax
  - 7.2.2.2. Smallpox
  - 7.2.2.3. Botulism
  - 7.2.2.4. Chemical
  - 7.2.2.5. Radiation/Nuclear
  - 7.2.2.6. Others
- 7.2.3. Rest of the World Biodefense Market Share and BPS Analysis, by Product Type, Value, 2023 and 2030
- 7.2.4. Rest of the World Biodefense Market Attractiveness Analysis, by Product Type, Value, 2023 - 2030
7.3. Rest of the World Biodefense Market Outlook, By End Use, 2019 - 2030
- 7.3.1. Key Highlights
- 7.3.2. Rest of the World Biodefense Market Outlook, by End Use, Value (US$ Million), 2019 - 2030
  - 7.3.2.1. Military
  - 7.3.2.2. Civil
  - 7.3.2.3. Research Institutes
- 7.3.3. Rest of the World Biodefense Market Share and BPS Analysis, by End Use, Value, 2023 and 2030
- 7.3.4. Rest of the World Biodefense Market Attractiveness Analysis, by End Use, Value, 2023 - 2030

8. Competitive Landscape

8.1. Heat Map Analysis
8.2. Company Profiles
- 8.2.1. Emergent Biosolutions, Inc.
  - 8.2.1.1. Company Overview
  - 8.2.1.2. Financial Performance
  - 8.2.1.3. Product Portfolio
  - 8.2.1.4. Pipeline Analysis
- 8.2.2. SIGA Technologies, Inc.
- 8.2.3. Bavarian Nordik A/S
- 8.2.4. GSK plc
- 8.2.5. Sanofi Pasteur
- 8.2.6. NightHawk Biosciences, Inc.
- 8.2.7. Soligenix
- 8.2.8. Arbutus Biopharma Corporation
- 8.2.9. Altimmune
- 8.2.10. Meridian Medical Technologies, LLC
- 8.2.11. Others